Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Celgene Corp (CELG)

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Celgene Corp 86 MORRIS AVENUE SUMMIT NJ 07901 USA

P: 908-673-9000

Description:

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.

Key Statistics

Overview:

Market Capitalization, $K 77,035,920
Shares Outstanding, K 711,714
Annual Sales, $ 15,281 M
Annual Net Income, $ 4,046 M
Last Quarter Sales, $ 4,520 M
Last Quarter Net Income, $ 1,691 M
60-Month Beta 1.41
% of Insider Shareholders 0.39%
% of Institutional Shareholders 71.66%
Float, K 708,938
% Float 99.61%

Growth:

1-Year Return 62.16%
3-Year Return -10.59%
5-Year Return -4.79%
5-Year Revenue Growth 135.31%
5-Year Earnings Growth 183.96%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.99 on 10/31/19
Next Earnings Date N/A
Earnings Per Share ttm 9.84
EPS Growth vs. Prev Qtr 5.36%
EPS Growth vs. Prev Year 35.47%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 06/26/14

CELG Ratios

Ratio
Price/Earnings ttm 10.99
Price/Earnings forward 12.02
Price/Earnings to Growth 0.51
Return-on-Equity % 78.15%
Return-on-Assets % 18.54%
Profit Margin % 26.48
Net Margin % 24.03
Debt/Equity 1.97
Price/Sales 5.04
Price/Cash Flow 12.19
Price/Book 6.37
Book Value/Share 16.98
Interest Coverage 7.52
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar